2
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction

, , , , , & show all
Pages 11-15 | Received 31 Aug 1992, Accepted 20 Sep 1993, Published online: 08 Jul 2009

References

  • Epstein S. Serum and urinary markers of bone remodelling: assessment of bone turnover. Endocr Rev 1988; 9: 437–49
  • Stepán J J., Silinkova-Malkova E, Havranek T, et al. Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 1983; 133: 189–200
  • Scarnecchia L, Minisola S, Pacitti M T., et al. Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 1991; 51: 517–24
  • Stépán J J., Lachmanová J, Straková M, Pacovsky V. Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. Bone Miner 1987; 3: 177–83
  • De la Piedra C, Torres R, Rapado A. Serum tartrate resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int 1989; 45: 58–60
  • Torres R, De la Píedra C, Rapado A. Clinical usefulness of serum tartrate-resistant acid phosphatases in Paget's disease of bone: correlation with other biochemical markers of bone remodelling. Calcif Tissues Int 1991; 49: 14–16
  • Uebelhart D, Gineyts E, Chapuy M C., Delmas P D. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990; 8: 87–96
  • Uebelhart D, Schlemmer A, Johansen J S., Gineyts E, Christiansen C, Delmas P D. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991; 72: 367–73
  • Eriksen E F., Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I Collagen formation and degradation in metabolic bone disease: correlation with bone histomorpho-metry. J Bone Miner Res 1993; 8: 127–32
  • Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635–40
  • Stewart A F., Vignery A, Silvergate A. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982; 55: 219–27
  • Horiuchi N, Caufield M P., Fisher J E., et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 1987; 238: 1566–68
  • Cohen Solal M E., Sebert J L., Boudailhez B, et al. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991; 73: 516–24
  • Fredlund P E., Ockerman P A., Vancy J D. Disappearance of intravenously infused acid hydrolases from the circulation in pigs. Acta Chir Scand 1973; 139: 19–25

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.